Table of Contents Table of Contents
Previous Page  181 / 1096 Next Page
Information
Show Menu
Previous Page 181 / 1096 Next Page
Page Background

S168

ESTRO 36

_______________________________________________________________________________________________

Figure: Contouring with the aid of MRI and CT. Red: GTV.

Green: pancreatic head. Blue: duodenum.

Conclusion

MRI-guided SBRT for pancreatic cancer with individually

evaluated margins is technical feasible and safe, with no

treatment related grade ≥3 toxicity. New strategies are

applied, including an individual corset to reduce breathing

motion, MRI based contouring and simulation of motion-

integrated dose distributions.

PV-0322 Rapid Early Response of Gastroesophageal

Junction Tumors During Real-time MRI-Guided

Radiotherapy

H. Musunuru

1

, S. Rosenberg

1

, J. Bayouth

1

, K. Mitteur

1

, M.

Ritter

1

, B. Paliwal

1

, M. Witek

1

, A. Baschnagel

1

, N.

Uboha

2

, S. Lubner

2

, N. Loconte

2

, P. Harari

1

, M. Bassetti

1

1

University of Wisconsin Hospital and Clinics, Radiation

Oncology, madison, USA

2

University of Wisconsin Hospital and Clinics, Medical

Oncology, Madison, USA

Purpose or Objective

Multimodality comprehensive therapy has become the

standard of care for locally advanced esophageal and

gastroesophageal junction tumors. Tumor response to

chemoradiation correlates with outcomes, however full

response information generally awaits esophagectomy.

Intra treatment predictors of response may allow

improved personalization of therapy. Daily MRI allows

direct quantification of GEJ tumor size. The aim of this

study is to evaluate volumetric changes in gross tumor

volume (GTV) for gastroesophageal junction (GEJ) cancer

patients undergoing MRI-guided radiation therapy, as part

of neoadjuvant chemoradiotherapy

Material and Methods

Five GEJ adenocarcinoma patients underwent MRI during

simulation and with each treatment fraction immediately

prior to radiation delivery. The GTV primary was

contoured on MRI scans at fractions 5, 10, 15, 20 and 23

and compared to the baseline GTV (Fig 1). Change in GTV

across time was expressed as percentage difference

(between baseline and different fractions and between

individual fractions) and in terms of absolute volume(cc).

Results

Median age and follow-up period for this cohort were 68

years and 46.5 days. The treatment regimen consisted of

weekly carboplatin (AUC 2mg/ml/min) and paclitaxel

(50mg/m

2

) with concurrent radiotherapy, 50.4Gy in 28

fractions in three patients and 41.4Gy in 23 fractions in

the remaining two patients. The earliest decrease in GTV

(% change) was noted at fraction 10 when compared to

baseline (Mean -52%, SD 4.6%; Fig 2A). Evaluation of

percentage change in the GTV between different fractions

(i.e. fraction 5 and fraction 10 etc.) also showed that the

earliest change occurred between fractions 5-10 (Table 1).

Mean (SD) of GTV at baseline and at fractions 5, 10, 15, 20

and 23 were 94.7cc(15.4), 93.9cc(14.8), 46.3cc(7.8),

39.7cc(6), 33.2cc(4.7) and 33.2cc(4.7), respectively.